Categories
Sanity Group

Research application initially rejected: Scientific pilot project on recreational cannabis in Frankfurt and Hanover denied regulatory approval

The project partners – comprising the scientific leads Prof. Dr. med. Kirsten Müller-Vahl (Medizinische Hochschule Hannover) and Prof. Dr. Heino Stöver (formerly Frankfurt University of Applied Sciences), as well as Sanity Group – disagree with the authority’s legal assessment: “We subjected the legal foundations of the research application to particularly thorough legal scrutiny and additionally secured them with an external legal report. It concluded that the research clause of Pillar 1 of the KCanG indeed provides a legal basis for scientifically designed pilot projects on recreational cannabis,” said Finn Hänsel, founder and CEO of Sanity Group. The report was made available to the authority during the review process.

Telemedicine debate makes legal alternatives more urgent
Sanity Group also views the BLE’s decision critically in light of current health policy developments. Ongoing discussions about stricter regulation of specialized telemedicine platforms in the medical cannabis sector threaten to cut off legal access for many people through the medical market. “We of course consider it the right step to make telemedical services available only to patients with serious health conditions. But if this area is more strictly regulated, there is an urgent need for legal alternatives. Otherwise, consumers who have so far at least obtained quality-assured products through the medical system instead of through illegal channels will be forced back into the illicit market – and thus back to unpredictable health risks,” Hänsel continued.

Such an outcome would run counter to the objectives of the Cannabis Act, which explicitly aims to strengthen health and youth protection while curbing the illicit market. “Pilot projects like those in Hanover and Frankfurt offer the chance to test scientifically sound and sensible solutions precisely for this need. This would create a clear separation between recreational use and medical therapy, provide a comprehensive data basis, and significantly relieve the medical care system.”

Looking to Switzerland underscores potential
The planned pilot projects were intended to scientifically study and evaluate, for the first time in Germany, the legal distribution of recreational cannabis in licensed specialty stores. The goal was to generate data for evidence-based regulation, similar to Switzerland, where comparable pilot projects have been providing valuable insights into consumption behavior, prevention, and illicit-market reduction since 2023.

“Home cultivation and cannabis clubs alone cannot meet demand in Germany; they are simply insufficient as legal sources of supply. Together with our partners, we will therefore continue to advocate that cannabis consumers are not once again left to the illegal market,” Hänsel emphasized. “And international experience proves us right: scientifically monitored pilot projects are the right path to combine health protection and consumer safety with effective illicit-market reduction.”

Health protection and illicit-market reduction: central research questions
In the study planned for Hanover and Frankfurt, registered adult participants were to be granted legal access to cannabis flowers and other THC-containing products at real market prices over a five-year period. The aim of the project was to investigate the effects of regulated cannabis distribution for recreational purposes – for example, on consumer health, youth protection, the illegal market, and organized crime. The project’s results could enable an evidence-based evaluation and provide a foundation for further decisions regarding cannabis legalization legislation.

EKOCAN evaluation results: pioneering insights
On Monday, initial interim results of the accompanying evaluation of KCanG were presented at a federal press conference, carried out by the joint research project “EKOCAN.” A key finding of the report: As of April 2025, production by cannabis cultivation associations covered less than 0.1 percent of total demand in Germany. Another reason, Hänsel argued, to make scientifically monitored pilot projects for specialized retail outlets possible. He views the publication of these interim results as an important opportunity to reinforce the case for pilot projects: “The findings strengthen our call for supplementary, scientifically monitored distribution models. It remains to be seen whether the results will also serve as a basis for adjustments to the KCanG or for the potential approval of pilot projects.”

 

About Sanity Group
Sanity Group aims to improve people’s quality of life through the use of cannabinoids and the utilization of the endocannabinoid system. The focus is on cannabinoid-based pharmaceuticals and consumer goods. To harness the full potential of cannabis, Sanity Group invests in research of the cannabis plant and its active ingredients as well as in specific areas of application. Sanity Group, founded in Berlin in 2018 by Finn Age Hänsel, includes Vayamed, avaay Medical and ZOIKS (medical cannabis), Endosane Pharmaceuticals (finished pharmaceuticals), vaay (lifestyle) and Grashaus Projects (recreational cannabis Swiss pilot project). Near Frankfurt am Main, Sanity Group also operates a logistics and production facility for cannabis pharmaceuticals. More information at sanitygroup.com/press.

Pressekontakt

Jennifer Plankenbühler

Pressesprecherin | Lead Medical PR

E-Mail: jennifer.plankenbuhler@sanitygroup.com | presse@sanitygroup.com

Phone: +49 (0) 173 37 62 845

Categories
Sanity Group

Coalition Agreement Presented: Sanity Group Welcomes Planned Evaluation of Cannabis Law and Calls for Scientific Pilot Projects

“It is the right step that the coalition intends to evaluate the Cannabis Act as planned, to assess how the partial legalization has impacted issues such as youth protection, public health, and fighting the illicit market,” says Finn Age Haensel, founder and CEO of Sanity Group. “At the same time, it is crucial to fully implement the law first. That is why we call for the prompt approval of scientific pilot projects for the distribution of recreational cannabis through licensed specialty stores. These will allow us to gain new insights based on solid data and practical experience. Only through a data-driven and scientifically grounded analysis can we implement the right measures to establish a quality-assured and responsible cannabis market while minimizing health risks to the population.” 

Ensuring Medical Care: Cannabis Patients in Focus 
In the field of medical cannabis, Sanity Group calls for continuous improvements in supply security. “The needs of patients must continue to be front and center. We advocate for widespread, low-threshold access to medical cannabis therapy that consistently upholds the highest standards of quality and safety,” explains Haensel. “Medical treatment with cannabis-based medicines should be made as accessible and straightforward as possible for all who need it.” 

With the evaluation of the Cannabis Act, the new government is sending a clear signal for an evidence-based approach to recreational cannabis. Sanity Group is convinced that the introduction of scientific pilot projects will promote the responsible distribution of cannabis and pave the way for a modern drug policy. 

About Sanity Group
Sanity Group aims to improve people’s quality of life through the use of cannabinoids and the utilization of the endocannabinoid system. The focus is on cannabinoid-based pharmaceuticals and consumer goods. To harness the full potential of cannabis, Sanity Group invests in research of the cannabis plant and its active ingredients as well as in specific areas of application. Sanity Group, founded in Berlin in 2018 by Finn Age Hänsel, includes Vayamed and avaay Medical (medical cannabis), Endosane Pharmaceuticals (finished pharmaceuticals), vaay (lifestyle) and Grashaus Projects (recreational cannabis Swiss pilot project). Near Frankfurt am Main, Sanity Group also operates a logistics and production facility for cannabis pharmaceuticals. More information at sanitygroup.com/press.

Press Contact

Jennifer Plankenbühler

Press Officer | Lead Medical PR

E-Mail: jennifer.plankenbuhler@sanitygroup.com | presse@sanitygroup.com

Phone: +49 (0) 173 37 62 845

Categories
Sanity Group

Cannabis Dispensaries in the German Capital: Sanity Group Plans Scientific Pilot Projects with Two Berlin Districts

At today’s press event, held at Pablo Neruda Central Library in Berlin, Clara Herrmann (Bündnis 90/Die Grünen), District Mayor of Friedrichshain-Kreuzberg, and Hannes Rehfeldt, CDU District Councilor for Social Affairs and Health in Neukölln, signed a letter of intent to carry out the pilot project. The scientific lead of the cannabis pilot study will include Professor Dr. Dr. Christian Ulrichs, Head of Urban Plant Ecophysiology at Humboldt-Universität zu Berlin. The dispensary concept for the project was developed by Sanity Group.

“The fact that Berlin districts have now also expressed their intention to implement cannabis pilot projects is, of course, something very special for us as a Berlin-based company,” said Finn Hänsel, founder and CEO of Sanity Group. “We are proud to contribute our expertise and experience in the design and operational implementation of this pilot project and to pioneer this effort directly in our city.” Protecting the health of consumers is one of the central objectives of Germany’s partial cannabis legalization, Hänsel added, emphasizing the need to shrink the illegal market as a priority. “Personal cultivation and cannabis clubs alone are not enough to provide consumers with access to safe, regulated cannabis and to sustainably combat the black market. This makes it all the more important to use scientific studies to set the course for achieving legalization goals. The fact that CDU, alongside the Green Party, is now driving such a project forward in Neukölln adds significant momentum.”

Five Years of Scientific Observation: Promoting Responsible Consumption as a Key Pillar
The pilot project will grant adult study participants legal access to cannabis products at dispensaries in the two districts. Participation requires meeting certain health criteria and engaging in regular scientific surveys as part of the study. Passing purchased products to third parties will result in immediate exclusion. To ensure that only study participants can shop at the dispensaries, they will receive a pseudonymized participant ID. This ID, read digitally by dispensary staff, will track which products and quantities have already been purchased at specific locations. A QR code on product packaging ensures that the legally permissible quantity is not exceeded.

To provide low-threshold intervention options, dispensary staff will be available to answer questions and address any signs of problematic consumption behavior. This allows for referrals to associated counseling services before potentially harmful addiction patterns may emerge. The dispensaries will use software from the Swiss company Cannavigia to document sales quantities and the entire supply chain, enabling individual analysis of consumption patterns. Additionally, regular workshops and informational events on responsible and reflective cannabis use will be a core component of the study.

Analysis Shows High Contamination in Berlin’s Illegal Cannabis
The urgency of curbing the illegal cannabis market to protect consumer health was highlighted by a recent laboratory analysis of black-market cannabis from 30 German cities, including Berlin. Samples revealed that over two-thirds of the tested cannabis contained traces of toxic pesticides, while around one-third was laced with substances like hairspray. Traces of other drugs, including cocaine and MDMA, were also detected. These findings underscore the critical need for clean cannabis from commercial supply chains, such as those enabled by pilot projects. The study will now evaluate whether licensed cannabis dispensaries can be a viable path toward this goal.

KCanWV: Regulation on Research Projects in Model Regions Officially Announced
Independent of the planned second pillar of the Cannabis Consumption Act (KCanG), under which model regions with specialized stores were to become reality, a draft regulation from the Federal Ministry of Food and Agriculture (BMEL) has been available since April 2024. This regulation designates the Federal Agency for Agriculture and Food (BLE) as the competent authority for research projects aimed at non-medical purposes. With the announcement by the ministry on Wednesday that the so-called “Cannabis Consumption Science Competency Regulation” (KCanWV) will come into effect, applications for relevant projects can be submitted to the BLE by research institutions and companies, starting from its publication in the Bundesgesetzblatt.

+++

You would like to stay updated on cannabis pilot projects in Germany and/or participate in potential future studies? Sign up for our newsletter at grashausprojects.de to follow all developments around cannabis dispensaries.

About Sanity Group
Sanity Group aims to improve people’s quality of life through the use of cannabinoids and the utilization of the endocannabinoid system. The focus is on cannabinoid-based pharmaceuticals and consumer goods. To harness the full potential of cannabis, Sanity Group invests in research of the cannabis plant and its active ingredients as well as in specific areas of application. Sanity Group, founded in Berlin in 2018 by Finn Age Hänsel, includes Vayamed and avaay Medical (medical cannabis), Endosane Pharmaceuticals (finished pharmaceuticals), vaay (lifestyle) and Grashaus Projects (recreational cannabis Swiss pilot project). Near Frankfurt am Main, Sanity Group also operates a logistics and production facility for cannabis pharmaceuticals. More information at sanitygroup.com/press.

Press Contact

Jennifer Plankenbühler

Lead Medical PR | Press Officer

E-Mail: jennifer.plankenbuhler@sanitygroup.com | presse@sanitygroup.com

Phone: +49 (0) 173 37 62 845